Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: BRAFV600 Mutation Clear all

Conditions: Melanoma
Interventions: LGX818; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Tumor, Solid, Pancreatic Cancer, Melanoma
Interventions: Ulixertinib, Palbociclib; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Malignant Melanoma
Interventions: vemurafenib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Saint Petersburgh, Florida + 5 more

Conditions: Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
Interventions: Radiation Therapy, Temozolomide, Veliparib; Radiation · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 25 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 145
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 111 more

Conditions: Malignant Melanoma
Interventions: Atezolizumab, Cobimetinib, Vemurafenib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Sarasota, Florida + 3 more

Conditions: BRAF or NRAS Mutant Metastatic Melanoma
Interventions: MEK162; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 10
States / cities: Fayetteville, Arkansas • Tampa, Florida • Portland, Oregon + 3 more

Conditions: Solid Tumor, Hematologic Malignancies
Interventions: LGX818; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 13
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • New Haven, Connecticut + 10 more

Conditions: BRAFV600 Mutation, Stage IV Melanoma
Interventions: Radiation therapy, Vemurafenib; Radiation · Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Neoplasm Metastasis
Interventions: CC-90003; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Los Angeles, California • New Haven, Connecticut • Charlotte, North Carolina + 1 more

Conditions: Metastatic Colorectal Cancer
Interventions: WNT974, LGX818, Cetuximab; Drug · Biological
Lead sponsor: Array BioPharma; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: New York, New York • Charleston, South Carolina • Houston, Texas + 1 more

Conditions: Non-small Cell Lung Cancer
Interventions: encorafenib, binimetinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 112
States / cities: Yuma, Arizona • Los Angeles, California • Santa Monica, California + 61 more

Conditions: Metastatic Melanoma
Interventions: vemurafenib + HD IL-2; Drug
Lead sponsor: Clinigen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 21
States / cities: Tucson, Arizona • La Jolla, California • Miami Beach, Florida + 18 more

Conditions: Malignant Melanoma, Neoplasms
Interventions: Tizanidine, Vemurafenib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Pleasant Hill, California • Detroit, Michigan • Durham, North Carolina

Conditions: Recurrent Melanoma, Stage IV Melanoma
Interventions: Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis; Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma
Interventions: Atezolizumab, Atezolizumab Placebo, Cobimetinib, Vemurafenib, Vemurafenib Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Tempe, Arizona • Springdale, Arkansas + 4 more

Search by objective public record fields.

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

LGX818 for Patients With BRAFV600 Mutated Tumors

Radiation Use During Vemurafenib Treatment

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma